TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8367976
Drug: sustained‐release bezafibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained‐release bezafibrate 400 mg daily (n = 21)
Study: 3788835
Drug: Oral-calcium supplementation
Normalized name: biotin / dicalcium phosphate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-calcium supplementation (1500 mg Ca++/day for 6 wk)
Study: 30227772
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon
Study: 22422777
Drug: GnRH-agonist (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-agonist (intranasal buserelin 600 mg per day starting on Day 21 of the preceding cycle)
Study: 22422777
Drug: GnRH-agonist (progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-agonist (progesterone >1.5 ng/ml)
Study: 22422777
Drug: GnRH-antagonist (progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-antagonist (progesterone >1.5 ng/ml)
Study: 16277137
Drug: Cognitive‐Behavioural Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioural Therapy (CBT) alone
Study: 16277137
Drug: SSRI antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI antidepressant therapy (fluoxetine) alone
Study: 16277137
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT plus fluoxetine
Study: 2652027
Drug: Povidone-iodine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 5% solution for 3 days before surgery
Study: 1183355
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg digoxin
Study: 19169265
Drug: D-004 (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-004 (320 mg) capsules administered daily for 6 weeks
Study: 10393475
Drug: Doxazosin (1-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-16 mg)
Study: 8938652
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 mg)
Study: 10393475
Drug: Terazosin (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1-2 mg)
Study: 6341944
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b (Hib) capsular polysaccharide vaccine
Study: 27562219
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen 1 hour before surgery and another 600 mg 6 hours after the first dose
Study: 27562219
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone 1 hour before surgery and another 4 mg 6 hours after the first dose
Study: 15718316
Drug: Iridium implant
Normalized name: iridium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iridium implant (IM) plus external-beam radiation therapy (EBRT)
Study: 9655717
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg budesonide twice daily
Study: 9655717
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg budesonide twice daily
Study: 7640129
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amethocaine gel 1 g (4% w/w)
Study: 7640129
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel 1 g
Study: 2671191
Drug: Biological mitral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mitral valves
Study: 25650733
Drug: Following the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the American College of Sports Medicine physical activity guidelines for body weight loss with 25-30% caloric restriction
Study: 24930512
Drug: Nebulized methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized methacholine inhalation (0.39 to 25 mg/ml)
Study: 23071344
Drug: Massage intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage intervention (weekly 45-minute massages for 4 weeks)
Study: 17589833
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75 mg
Study: 27254743
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg daily)
Study: 28619696
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (mainly antipyretic analgesics, nonsteroidal anti-inflammatory drugs, opioids)
Study: 28619696
Drug: Acute opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute opioid treatments
Study: 28619696
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (intravenous morphine)
Study: 25759961
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation (10 mg Zn/day) and venous zinc administration (0.06537 mg Zn/kg of body weight) in the experimental group.
Study: 21042875
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (N = 40; 1.8 g/day, EPA + DHA = 864 mg)
Study: 17550932
Drug: Aminoguanidine (iNOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoguanidine (iNOS inhibitor)
Study: 9354206
Drug: Oral benzocaine
Normalized name: benzocaine Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral benzocaine 0.75% solution (n = 14)
Study: 20831528
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 5 mg/kg/h for 6 hours for 6 successive days
Study: 15867559
Drug: C-labeled nandrolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-labeled nandrolone (25 mg dose, followed by a second identical dose 24 hours later)
Study: 28121172
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation consisting of 12 weeks of physical exercise training and monthly psycho-educational consultations
Study: 19671410
Drug: Shengmai (SM)
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai (SM) Capsule
Study: 17077230
Drug: Standard access
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard access to emergency contraceptive pills (pills dispensed when needed at usual charges)
Study: 17077230
Drug: Increased access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased access to emergency contraceptive pills
Study: 11531217
Drug: Choline-supplemented TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-supplemented TPN (2 g choline chloride added)
Study: 3069751
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of 100 mg ibopamine (SIMES formulations)
Study: 24584382
Drug: Mebeverine 135mg
Normalized name: mebeverine
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 135mg twice daily
Study: 18450862
Drug: European Bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Bladder Dysfunction Study treatment
Study: 8718542
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate (Ca) 2 g/day (Group-Ca)
Study: 1400926
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of oestradiol valerate (2 mg, days 1-28) and levonorgestrel (75 micrograms, days 17-28)
Study: 1400926
Drug: Continuous combination
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combination of oestradiol valerate (2 mg, days 1-28) and cyproterone acetate (1 mg, days 1-28)
Study: 2935765
Drug: 1% etidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% etidocaine 5 mL dropped on each fallopian tube before tubal banding
Study: 2935765
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anesthetic agent
Study: 2935765
Drug: 1% etidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% etidocaine 5 mL
Study: 22796902
Drug: Polyphenol-rich dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich dark chocolate (DC) 20 g containing 500 mg polyphenols
Study: 17088909
Drug: Cumulative anthracycline
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative anthracycline dose
Study: 8831364
Drug: Verapamil (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.15 mg/kg)
Study: 25130503
Drug: Cluster immunotherapy
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster immunotherapy with high polymerized allergen extract of grass/rye pollen mixture
Study: 19967558
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg daily)
Study: 18696285
Drug: Clonidine adhesive
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine adhesive patch (1.0mg, 1.5mg, or 2.0mg per week for 4 weeks)
Study: 18696285
Drug: Placebo adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adhesive patch
Study: 9613269
Drug: Vecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.2 mg.kg‐1
Study: 8598261
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) at low dosage
Study: 22743160
Drug: Drug Counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Counseling (DC)
Study: 18751444
Drug: Paclitaxel (PTX)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PTX) 80 mg/m2 weekly
Study: 18751444
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 12.5 mg/m2 every two weeks
Study: 18751444
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PTX and PLD
Study: 12873918
Drug: 1 micro
Normalized name: SAIF 1 Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 micro g/kg IV fentanyl 10 min before discontinuation of anesthetic
Study: 11783029
Drug: Carboplatin solution
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin solution (injection group)
Study: 29126686
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion threshold of Hb 80 g/L
Study: 29126686
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion threshold of Hb 100 g/L
Study: 24606873
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy for Anorexia Nervosa (CBT-AN)
Study: 11550961
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg doxycycline twice a day
Study: 7933707
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (200 or 400 mg)
Study: 3284491
Drug: Glucose-containing priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing priming solutions
Study: 1106289
Drug: Same treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same treatment by private physician.
Study: 28917226
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily energy intake <50% of requirement (Group A)
Study: 28917226
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily energy intake >=50% of requirement (Group B)
Study: 25776489
Drug: Catheter administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catheter administration of bupivacaine in female patients
Study: 19954717
Drug: Thrombo (EIPICO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombo (EIPICO, Egypt) 75 mg tablets
Study: 16765700
Drug: timolol‐pilocarpine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol‐pilocarpine combination
Study: 7064850
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg)
Study: 3222686
Drug: (+/-)-nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/-)-nicardipine (20 mg)
Study: 15575343
Drug: Orlistat (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (360 mg/d)
Study: 9782075
Drug: 135 mg
Normalized name: cocaine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg m-2 paclitaxel administered by 3-hour infusion
Study: 7929727
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management with hospitalization, intravenous hydration, and supportive therapy.
Study: 23425051
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injection and balloon dilatation
Study: 23425051
Drug: Steroid application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid application and balloon dilatation
Study: 18832295
Drug: Vildagliptin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 25 to 200 mg qd
Study: 18832295
Drug: Vildagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 200 mg qd
Study: 15631798
Drug: Cefoperazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone plus sulbactam (sulperazon) (2 g i.v. before and after surgery)
Study: 11052511
Drug: 2 percent
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GEL [The Keeps ETHANOL 62 percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 percent diltiazem gel
Study: 1524960
Drug: pH-feedback controlled
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-feedback controlled infusion of ranitidine
Study: 1524960
Drug: fixed-rate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fixed-rate infusion of ranitidine
Study: 1524960
Drug: fixed-dose infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fixed-dose infusion of ranitidine
Study: 30281086
Drug: CBT2go (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT2go (cognitive behavioral therapy combined with automated thought challenging/adaptive behavior)
Study: 20932581
Drug: Baerveldt glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt glaucoma implant (BGI; model 101-350)
Study: 15074089
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of human chorionic gonadotropine (hCG)
Study: 9720158
Drug: Intraoperative bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative bleeding from aneurysms of the ophthalmic segment of ICA (19 cases)
Study: 12030915
Drug: 2.5% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% testosterone gel preparation
Study: 1103113
Drug: Feprazone 450
Normalized name: feprazone
DrugBank: Feprazone (DB13364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feprazone 450 mg daily
Study: 6088300
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg daily
Study: 31364144
Drug: Oral supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplements (OS) with immune-stimulating molecules (Group 2 and 3)
Study: 31364144
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for rhinitis and OME (Control group)
Study: 28715908
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure treatment (N=36)
Study: 16884344
Drug: Control (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (n = 22) - no treatment
Study: 14626377
Drug: Short-term hormone
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term hormone therapy (HT)
Study: 19505307
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone therapy (HT)
Study: 1390495
Drug: Cyclophosphamide 1
Normalized name: cyclophosphamide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 1 g intravenous boluses monthly
Study: 3893815
Drug: Indobufen 100
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 100 mg b.d.
Study: 3893815
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg b.d.
Study: 27682493
Drug: Compound monoammonium
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound monoammonium glycyrrhizinate combined with dandelion (TCM group)
Study: 29771077
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Control group)
Study: 18625920
Drug: SPs making
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPs making brand-specific medication requests
Study: 11822921
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of hyaluronate sodium at a concentration of 10 mg/mL
Study: 31995811
Drug: Varenicline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline administration
Study: 28459236
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day sugarcane bagasse plus conventional treatment
Study: 20015433
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus conventional treatment
Study: 24481688
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin supplementation (220 μg folic acid, 1.1 mg vitamin B2, 0.73 mg B6, 1.2 μg B12, 130 mg calcium)
Study: 24742970
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg/day)
Study: 24742970
Drug: Combined aliskiren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined aliskiren (150 mg/day) and losartan (100 mg/day)
Study: 6756484
Drug: No‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No‐treatment control group
Study: 10886592
Drug: R‐568 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐568 (100 mg)
Study: 1559738
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg twice daily
Study: 3902362
Drug: PGE2 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 (0.5 mg) administered every 4 h via nasogastric tube
Study: 30469412
Drug: Synergy 1
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy 1 (10 g/day)
Study: 26111826
Drug: Continuous-fingolimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-fingolimod 0.5 mg
Study: 22910291
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 treatment for 1 year
Study: 17969401
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with aromatase inhibitors (anastrazole or exemestane)
Study: 11793169
Drug: Menatetrenone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (45 mg/day, daily; n = 23)
Study: 11793169
Drug: Etidronate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (200 mg/day, 14 days per 3 months; n = 25)
Study: 11793169
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate (2 g/day, daily; n = 24)
Study: 8005130
Drug: verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 360 mg.day-1
Study: 2679444
Drug: Gestrinone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (2 x 2.5 mg/week)
Study: 2679444
Drug: Danazol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (3 x 200 mg/day)
Study: 23647007
Drug: Tx 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tx 4: no further treatment (control)
Study: 19860888
Drug: 0.5% PRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% PRO 2000/5 gel
Study: 16032448
Drug: CEI (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI (Conventional continuous epidural infusion)
Study: 12399689
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised brushing with 1,500-ppm fluoride toothpaste and rinsing with a beaker of water (School A)
Study: 12399689
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised brushing with 1,500-ppm fluoride toothpaste and only permitted to spit out once after brushing (School B)
Study: 12399689
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily brushing and no supply of toothpaste (School C)
Study: 30138384
Drug: Ranibizumab monotherapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monotherapy
Study: 19190496
Drug: 18-month lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 18-month lamivudine monotherapy
Study: 17259157
Drug: Estrogen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (3 mg estrostilben thrice a day from the day before acrinol injection to the end of delivery)
Study: 10329858
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no estrogen treatment)
Study: 11501645
Drug: Cream A
Normalized name: KIT, CREAM AND GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream A (high lipid content)
Study: 11501645
Drug: Cream B
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream B (moderate/low lipid content)
Study: 24009792
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass drug administration (MDA) aiming for coverage of children between 80%-90%
Study: 24009792
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass drug administration (MDA) aiming for coverage > 90%
Study: 24009792
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass drug administration (MDA) for three years